Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158441107> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2158441107 endingPage "27" @default.
- W2158441107 startingPage "20" @default.
- W2158441107 abstract "This randomized, double-blinded, double-dummy, parallel-group, single-center study compared a single dose of the novel selective COX-2 inhibitor lumiracoxib (400 mg), with celecoxib (400 mg) or placebo in dental pain. Patients ≥17 years with moderate-to-severe dental pain were recruited after surgical extraction of 2 or more partially or fully bony impacted molars. Pain intensity was measured using the categorical scale and the primary efficacy variable was the summed pain intensity difference over 8 hours after dosing (SPID-8). Patient disposition and demographics were comparable between lumiracoxib 400 mg (n = 156), celecoxib 400 mg (n = 156), and placebo (n = 52) groups. Lumiracoxib was statistically superior (P < .001) to both celecoxib and placebo in reducing pain intensity (SPID-8; least-squares means: 8.31, lumiracoxib; 4.26, celecoxib; −1.87, placebo). Significantly more patients treated with lumiracoxib (58.9%) considered treatment to be good or excellent compared with celecoxib and placebo (42.3% and 5.7%, respectively; P = .001). Lumiracoxib was superior to celecoxib and placebo for all other secondary efficacy variables. All treatments were well-tolerated. In conclusion, 400 mg lumiracoxib was well-tolerated and provided significantly superior analgesia to 400 mg celecoxib or placebo in patients with moderate-to-severe pain after dental surgery. Perspective In a randomized, double-blinded, double-dummy, parallel-group, single-center study, a single dose of the novel selective COX-2 inhibitor lumiracoxib (400 mg) was well-tolerated and provided significantly superior analgesia to 400 mg celecoxib or placebo in patients with moderate-to-severe dental pain after surgical extraction of impacted molars." @default.
- W2158441107 created "2016-06-24" @default.
- W2158441107 creator A5009434397 @default.
- W2158441107 creator A5012985677 @default.
- W2158441107 creator A5029817494 @default.
- W2158441107 creator A5062705684 @default.
- W2158441107 date "2008-01-01" @default.
- W2158441107 modified "2023-10-15" @default.
- W2158441107 title "Lumiracoxib 400 mg Compared With Celecoxib 400 mg and Placebo for Treating Pain Following Dental Surgery: A Randomized, Controlled Trial" @default.
- W2158441107 cites W1525118763 @default.
- W2158441107 cites W1911671061 @default.
- W2158441107 cites W1961189376 @default.
- W2158441107 cites W1993513535 @default.
- W2158441107 cites W2002667071 @default.
- W2158441107 cites W2015598845 @default.
- W2158441107 cites W2020846765 @default.
- W2158441107 cites W2022594313 @default.
- W2158441107 cites W2023622543 @default.
- W2158441107 cites W2053048167 @default.
- W2158441107 cites W2054195861 @default.
- W2158441107 cites W2057969209 @default.
- W2158441107 cites W2063691905 @default.
- W2158441107 cites W2090079955 @default.
- W2158441107 cites W2094764760 @default.
- W2158441107 cites W2097724942 @default.
- W2158441107 cites W2158735781 @default.
- W2158441107 cites W2161715178 @default.
- W2158441107 cites W2414921526 @default.
- W2158441107 doi "https://doi.org/10.1016/j.jpain.2007.08.004" @default.
- W2158441107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17933588" @default.
- W2158441107 hasPublicationYear "2008" @default.
- W2158441107 type Work @default.
- W2158441107 sameAs 2158441107 @default.
- W2158441107 citedByCount "11" @default.
- W2158441107 countsByYear W21584411072012 @default.
- W2158441107 countsByYear W21584411072013 @default.
- W2158441107 countsByYear W21584411072014 @default.
- W2158441107 countsByYear W21584411072015 @default.
- W2158441107 crossrefType "journal-article" @default.
- W2158441107 hasAuthorship W2158441107A5009434397 @default.
- W2158441107 hasAuthorship W2158441107A5012985677 @default.
- W2158441107 hasAuthorship W2158441107A5029817494 @default.
- W2158441107 hasAuthorship W2158441107A5062705684 @default.
- W2158441107 hasBestOaLocation W21584411071 @default.
- W2158441107 hasConcept C126322002 @default.
- W2158441107 hasConcept C142724271 @default.
- W2158441107 hasConcept C204787440 @default.
- W2158441107 hasConcept C27081682 @default.
- W2158441107 hasConcept C2776467144 @default.
- W2158441107 hasConcept C42219234 @default.
- W2158441107 hasConcept C71924100 @default.
- W2158441107 hasConceptScore W2158441107C126322002 @default.
- W2158441107 hasConceptScore W2158441107C142724271 @default.
- W2158441107 hasConceptScore W2158441107C204787440 @default.
- W2158441107 hasConceptScore W2158441107C27081682 @default.
- W2158441107 hasConceptScore W2158441107C2776467144 @default.
- W2158441107 hasConceptScore W2158441107C42219234 @default.
- W2158441107 hasConceptScore W2158441107C71924100 @default.
- W2158441107 hasIssue "1" @default.
- W2158441107 hasLocation W21584411071 @default.
- W2158441107 hasLocation W21584411072 @default.
- W2158441107 hasOpenAccess W2158441107 @default.
- W2158441107 hasPrimaryLocation W21584411071 @default.
- W2158441107 hasRelatedWork W1527522883 @default.
- W2158441107 hasRelatedWork W2140481652 @default.
- W2158441107 hasRelatedWork W2158441107 @default.
- W2158441107 hasRelatedWork W2167998601 @default.
- W2158441107 hasRelatedWork W2618196413 @default.
- W2158441107 hasRelatedWork W2619461160 @default.
- W2158441107 hasRelatedWork W2765302917 @default.
- W2158441107 hasRelatedWork W4235710562 @default.
- W2158441107 hasRelatedWork W4236625742 @default.
- W2158441107 hasRelatedWork W4362568561 @default.
- W2158441107 hasVolume "9" @default.
- W2158441107 isParatext "false" @default.
- W2158441107 isRetracted "false" @default.
- W2158441107 magId "2158441107" @default.
- W2158441107 workType "article" @default.